Adlai Nortye (ANL) Competitors $2.08 +0.03 (+1.46%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ANL vs. ATYR, DSGN, IMMP, ELDN, CTNM, YMAB, HRTX, ITOS, AQST, and LFVNShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Atyr PHARMA (ATYR), Design Therapeutics (DSGN), Immutep (IMMP), Eledon Pharmaceuticals (ELDN), Contineum Therapeutics (CTNM), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Atyr PHARMA Design Therapeutics Immutep Eledon Pharmaceuticals Contineum Therapeutics Y-mAbs Therapeutics Heron Therapeutics iTeos Therapeutics Aquestive Therapeutics LifeVantage Atyr PHARMA (NASDAQ:ATYR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership. Which has better valuation and earnings, ATYR or ANL? Atyr PHARMA has higher earnings, but lower revenue than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,352.00-$50.39M-$0.94-4.03Adlai Nortye$5M15.35-$104.87MN/AN/A Do insiders & institutionals have more ownership in ATYR or ANL? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor ATYR or ANL? In the previous week, Adlai Nortye had 2 more articles in the media than Atyr PHARMA. MarketBeat recorded 7 mentions for Adlai Nortye and 5 mentions for Atyr PHARMA. Adlai Nortye's average media sentiment score of 0.95 beat Atyr PHARMA's score of 0.70 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ATYR or ANL? Atyr PHARMA has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -1.38, indicating that its share price is 238% less volatile than the S&P 500. Is ATYR or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Adlai Nortye N/A N/A N/A Does the MarketBeat Community prefer ATYR or ANL? Atyr PHARMA received 2 more outperform votes than Adlai Nortye when rated by MarketBeat users. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes10100.00% Underperform VotesNo VotesAdlai NortyeOutperform Votes8100.00% Underperform VotesNo Votes Do analysts recommend ATYR or ANL? Atyr PHARMA presently has a consensus price target of $19.25, suggesting a potential upside of 408.59%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 332.69%. Given Atyr PHARMA's higher probable upside, equities analysts plainly believe Atyr PHARMA is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtyr PHARMA beats Adlai Nortye on 8 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.75M$6.87B$5.57B$9.13BDividend YieldN/A2.90%5.31%3.98%P/E RatioN/A4.7759.1514.12Price / Sales15.35336.561,222.7486.17Price / CashN/A73.5045.9637.70Price / BookN/A5.315.174.72Net Income-$104.87M$137.00M$111.17M$224.32M7 Day Performance-2.12%0.18%0.78%0.50%1 Month Performance-22.68%0.98%3.85%2.13%1 Year Performance-77.22%8.72%26.24%21.21% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.6503 of 5 stars$2.08+1.5%$9.00+332.7%-77.2%$76.75M$5M0.00127Short Interest ↓News CoverageATYRAtyr PHARMA2.681 of 5 stars$3.46-3.6%$19.25+456.4%N/A$290.43M$350,000.00-3.6853Short Interest ↑News CoveragePositive NewsDSGNDesign Therapeutics2.0021 of 5 stars$5.06+1.8%$7.00+38.3%+110.6%$286.50MN/A-5.9540Short Interest ↑News CoverageIMMPImmutep1.9911 of 5 stars$1.94-1.3%$8.50+338.1%-3.3%$282.39M$5.14M0.002,021News CoveragePositive NewsGap UpELDNEledon Pharmaceuticals3.1138 of 5 stars$4.66+5.2%$16.00+243.3%+158.4%$278.39MN/A-2.3210Analyst ForecastShort Interest ↓CTNMContineum Therapeutics3.288 of 5 stars$10.78-3.6%$29.25+171.3%N/A$277.91M$50M0.0031Upcoming EarningsYMABY-mAbs Therapeutics2.3572 of 5 stars$6.15-1.6%$20.89+239.7%-50.6%$275.46M$84.82M-11.39150Positive NewsHRTXHeron Therapeutics3.8961 of 5 stars$1.81-1.1%$5.67+213.1%-30.5%$275.30M$127.04M-10.05300Analyst DowngradeNews CoverageITOSiTeos Therapeutics4.0869 of 5 stars$7.53-1.4%$22.25+195.5%-23.7%$275.07M$12.60M-2.3990Short Interest ↓Positive NewsAQSTAquestive Therapeutics1.4276 of 5 stars$2.99-3.2%$11.00+267.9%+29.4%$272.63M$50.58M-6.64160Short Interest ↑LFVNLifeVantage4.3605 of 5 stars$21.51-11.3%$30.50+41.8%+284.2%$269.31M$200.16M67.22260Upcoming Earnings Related Companies and Tools Related Companies Atyr PHARMA Alternatives Design Therapeutics Alternatives Immutep Alternatives Eledon Pharmaceuticals Alternatives Contineum Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Heron Therapeutics Alternatives iTeos Therapeutics Alternatives Aquestive Therapeutics Alternatives LifeVantage Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANL) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts